PMID- 36568640
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221227
IS  - 1687-8450 (Print)
IS  - 1687-8469 (Electronic)
IS  - 1687-8450 (Linking)
VI  - 2022
DP  - 2022
TI  - Evaluation of Transarterial Chemoembolization Protocol with Drug-Eluting Beads in 
      Combination with Lipiodol for Hepatocellular Carcinoma: A Single-Center 
      Controlled Study.
PG  - 1090313
LID - 10.1155/2022/1090313 [doi]
LID - 1090313
AB  - OBJECTIVES: To evaluate the efficacy and safety of transarterial 
      chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and lipiodol 
      (DEB-Lipiodol TACE) in the treatment of unresectable hepatocellular carcinoma 
      (HCC) patients. MATERIALS AND METHODS: The medical records of consecutive 
      unresectable HCC patients who underwent DEB-TACE or DEB-Lipiodol TACE from June 
      2016 to July 2021 were retrospectively evaluated. Therapeutic response, overall 
      survival (OS), progression-free survival (PFS), and adverse events (AEs) were 
      compared among the groups. RESULTS: Three hundred and twenty-seven patients were 
      enrolled in the study, including 293 patients in the DEB-TACE group and 34 
      patients in the DEB-Lipiodol TACE group. The objective response rate in the 
      DEB-Lipiodol TACE group was 17.6%, significantly higher than that in the DEB-TACE 
      group (5.8%, P=0.011). Similarly, DEB-Lipiodol TACE group also had a higher 
      disease control rate (91.2% vs 68.6%, P=0.006). Median OS was 13 months (95% CI: 
      11.0 months and 15.0 months) and 22 months (95% CI: 17.3 months and 26.7 months) 
      in the DEB-TACE group and DEB-Lipiodol TACE group, respectively (P=0.041). 
      Meanwhile, median PFS was 7 months (95% CI: 5.2 months and 8.8 months) in the 
      DEB-TACE group and 12 months (95% CI: 7.9 months and 16.1 months) in the 
      DEB-Lipiodol TACE group (P=0.174). There was no statistically significant 
      difference in AEs incidence among the two groups (P > 0.05). CONCLUSIONS: 
      DEB-Lipiodol TACE was safe, well tolerated, and had a better efficacy compared 
      with DEB-TACE in unresectable HCC patients.
CI  - Copyright (c) 2022 Xiangjun Dong et al.
FAU - Dong, Xiangjun
AU  - Dong X
AUID- ORCID: 0000-0001-9491-9461
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
AD  - Hubei Provinve Key Laboratory of Molecular Imaging, Wuhan 430022, China.
FAU - Wang, Ying
AU  - Wang Y
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
AD  - Hubei Provinve Key Laboratory of Molecular Imaging, Wuhan 430022, China.
FAU - Hao, Jieya
AU  - Hao J
AD  - Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University 
      of Science and Technology, Wuhan, China.
FAU - Chen, Lei
AU  - Chen L
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
AD  - Hubei Provinve Key Laboratory of Molecular Imaging, Wuhan 430022, China.
FAU - Sun, Tao
AU  - Sun T
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
AD  - Hubei Provinve Key Laboratory of Molecular Imaging, Wuhan 430022, China.
FAU - Zhang, Weihua
AU  - Zhang W
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
AD  - Hubei Provinve Key Laboratory of Molecular Imaging, Wuhan 430022, China.
FAU - Sun, Bo
AU  - Sun B
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
AD  - Hubei Provinve Key Laboratory of Molecular Imaging, Wuhan 430022, China.
FAU - Zhu, Licheng
AU  - Zhu L
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
AD  - Hubei Provinve Key Laboratory of Molecular Imaging, Wuhan 430022, China.
FAU - Guo, Yusheng
AU  - Guo Y
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
AD  - Hubei Provinve Key Laboratory of Molecular Imaging, Wuhan 430022, China.
FAU - Zheng, Chuansheng
AU  - Zheng C
AUID- ORCID: 0000-0002-2435-1417
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
AD  - Hubei Provinve Key Laboratory of Molecular Imaging, Wuhan 430022, China.
LA  - eng
PT  - Journal Article
DEP - 20221214
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC9771663
COIS- All authors declare that they have no conflicts of interest.
EDAT- 2022/12/27 06:00
MHDA- 2022/12/27 06:01
PMCR- 2022/12/14
CRDT- 2022/12/26 03:56
PHST- 2022/10/08 00:00 [received]
PHST- 2022/11/29 00:00 [revised]
PHST- 2022/12/01 00:00 [accepted]
PHST- 2022/12/26 03:56 [entrez]
PHST- 2022/12/27 06:00 [pubmed]
PHST- 2022/12/27 06:01 [medline]
PHST- 2022/12/14 00:00 [pmc-release]
AID - 10.1155/2022/1090313 [doi]
PST - epublish
SO  - J Oncol. 2022 Dec 14;2022:1090313. doi: 10.1155/2022/1090313. eCollection 2022.